Skip to content Accessibility statement

Professor Andrea Manca Presents at Key HTA and Dermatology Events

News

Posted on Tuesday 2 December 2025

Professor Manca shared expertise with NICE and the British Association of Dermatologists on the methods for individualised HTA and the opportunities offered by real-world data to assess the value of eczema therapies.

NICE HTA Lab Stakeholders Workshop

Professor Manca delivered a talk titled “From population to individuals: What NICE may need to consider to adapt its decision-making analytical framework towards individualisation” as part of the Stakeholder Workshop series “The Future of HTA with AI”, organised by the NICE HTA Lab in November 2025.

The HTA Lab provides a collaborative “sandbox” environment where stakeholders can co-create and test new approaches without affecting live NICE evaluations. It supports innovation in evaluating health technologies and developing solutions for complex challenges faced by NICE.

The value of clinical registers to assess eczema therapies

Professor Manca also recently spoke at the one-day networking event “A-STAR: Going Deeper”, organised by the British Association of Dermatologists in London. His talk, “A-STAR is born: Opportunities to assess the value for money of advanced systemic therapies in routine clinical practice”, highlighted the role of real-world evidence in assessing both clinical effectiveness and cost-effectiveness of systemic therapies for atopic eczema.

A-STAR (The UK-Irish Atopic Eczema Systemic Therapy Register) is an observational study tracking the safety, efficacy, and real-world costs of systemic immuno-modulators in patients of all ages with atopic eczema. By following patients’ care through their local dermatologists, the register aims to inform clinical decisions and improve patient outcomes. 

The event brought together academics, industry representatives, clinicians, and other experts focused on improving care for people with eczema.

About Professor Andrea Manca

Professor Andrea Manca is an applied health economist working at the intersection of academia and health policy. He has extensive experience collaborating with HTA agencies, clinicians, patient organisations, and industry stakeholders, providing evidence to inform health technology decisions and policy development. 

Learn more about his research here.